Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...

Monalizumab is a first-in-class broad-spectrum immune checkpoint inhibitor with a dual effect on both Natural Killer (NK) cells and T lymphocytes Monalizumab showed promising preclinical and clinical...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the appointment of six leading experts to its newly formed Strategic Advisory Board (SAB). The SAB will work with...

Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates...

These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-based chemotherapy and PD-1/L1 inhibitors...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access...

Confirmation of previously reported response rate and new data on durability of response reinforces the potential anti-tumor activity of the monalizumab cetuximab combination Clinical program advances...

Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and cetuximab on Monday, October 22, 4pm CEST (10 am EDT) Innate Pharma SA (the “Company” - Euronext Paris...

Oral presentation on data with longer follow-up of dose escalation patients and new data from cohort expansion in the Phase I study at the EORTC CLTF 2018 Meeting IPH4102 showed encouraging clinical...